FEATURED ARTICLES
Clinical Leader news roundup for the week of April 11, 2016, with articles on pharma’s investment in patients, FitBit activity trackers in clinical trials, new Hep C combination treatment tested in Malaysia and Thailand, prostate and pancreatic cancer trials, the need for clinical trial participants, and making the most of clinical trial data.
-
How Do I Get My Compound Into Phase I?
The primary challenge for pharmaceutical and biotechnology companies in developing their drugs is to carefully assess the relationship between efficacy and toxicity prior to entering into human clinical trials. By Dr. Scott E. Boley and Greg Ruppert
-
Will Protagonist Be The Hero In Making Stable Oral Peptides To Replace Injectables?
Protagonist Therapeutics has created a technology for making stable oral peptides capable of replacing injectable-only drugs and is developing entirely new oral-peptide therapeutics or GI patients. Its initial development areas are irritable bowel diseases (IBD) and irritable bowel syndrome (IBS). Two compounds, one an injectable peptide to block IL-6, and another, an oral peptide to block integrins, will enter clinical trials in 2015.
-
Can Rapid Mobile Diagnostics Speed Up Clinical Trials And Regulatory Reviews?
As a new technological space containing all the alternatives, the most practical and immediate application for Rapid Mobile Diagnostics (RMDx) may be in clinical trials.